Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX1 | P09601 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 10/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532938 | 0.84 | MET (0.50) | HMOX1METMAPK3MAPK1MAP2K1 | |
| SCHEMBL4080008 | 0.82 | HMOX1 (0.49) | HMOX1METMAPK3MAPK1MAP2K1 | |
| SCHEMBL4090591 | 0.80 | MET (0.57) | HMOX1METMAPK1FLT3RBP4 | |
| SCHEMBL9889385 | 0.78 | MAPT (0.55) | METMAPK3MAPK1MAP2K1FLT3 | |
| SCHEMBL4713595 | 0.77 | MET (0.50) | HMOX1METMAPK3MAPK1MAP2K1 | |
| SCHEMBL5257069 | 0.77 | MAPK1 (0.63) | HMOX1METMAPK3MAPK1MAP2K1 | |
| SCHEMBL2972760 | 0.74 | RBP4 (0.52) | HMOX1METMAPK3MAPK1MAP2K1 | |
| SCHEMBL4091919 | 0.74 | CTSS (0.64) | — | |
| SCHEMBL5126874 | 0.73 | HMOX1 (0.52) | HMOX1METMAPK3MAPK1MAP2K1 | |
| SCHEMBL4083458 | 0.72 | HMOX1 (0.51) | HMOX1METMAPK3MAPK1MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | HMOX1 2517/4885MET 4449/4885MAPK3 2502/4885 |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | HMOX1 2401/4885MET 3516/4885MAPK3 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.